133 related articles for article (PubMed ID: 12101579)
1. [Second-line chemotherapy for ovarian cancer: the potential of Taxol].
Maksimov SIa
Vopr Onkol; 2002; 48(1):99-101. PubMed ID: 12101579
[No Abstract] [Full Text] [Related]
2. [Paclitaxel (Taxol)--drug of choice in ovarian cancer].
Fishman A
Harefuah; 1996 Apr; 130(8):557-60. PubMed ID: 8765885
[No Abstract] [Full Text] [Related]
3. [Chemotherapy of ovarian and breast cancer with Taxol].
Dtsch Med Wochenschr; 1996 Dec; 121(50 Suppl):1-12. PubMed ID: 9022362
[No Abstract] [Full Text] [Related]
4. [Taxol].
Kühnle H
Zentralbl Gynakol; 1996; 118(10):580. PubMed ID: 8999717
[No Abstract] [Full Text] [Related]
5. [Taxol in the treatment of ovarian neoplasm].
Wang Y; Huang R; Huang H
Zhonghua Fu Chan Ke Za Zhi; 1999 Jul; 34(7):439-41. PubMed ID: 11360659
[No Abstract] [Full Text] [Related]
6. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T
Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068
[TBL] [Abstract][Full Text] [Related]
7. [The role of paclitaxel in the first line treatment of cancer of the ovary?].
Slimane K
Bull Cancer; 2003 Mar; 90(3):202-3. PubMed ID: 12803089
[No Abstract] [Full Text] [Related]
8. NICE approves Taxol for ovarian cancer.
Kmietowicz Z
BMJ; 2000 May; 320(7245):1293. PubMed ID: 10807610
[No Abstract] [Full Text] [Related]
9. [Choice of first-line chemotherapy for advanced ovarian cancer].
Tiuliandin SA
Vopr Onkol; 1999; 45(4):350-4. PubMed ID: 10532090
[No Abstract] [Full Text] [Related]
10. Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates.
McGuire WP
J Clin Oncol; 2009 Oct; 27(28):4633-4. PubMed ID: 19704055
[No Abstract] [Full Text] [Related]
11. Paclitaxel in advanced ovarian cancer: too much optimism?
Bulusu VR; Allerton R
Gynecol Oncol; 1997 Aug; 66(2):335-6. PubMed ID: 9264587
[No Abstract] [Full Text] [Related]
12. [Comparative clinical appraisal of the effectiveness and tolerability of paclitaxel-LANCE and taxol in combination chemotherapy for recurrences and platinum-refractory ovarian carcinoma].
Gershanovich ML; Makhnova EV; Livshits ME; Gulo EI
Vopr Onkol; 2004; 50(6):716-9. PubMed ID: 15755070
[TBL] [Abstract][Full Text] [Related]
13. Report from ASCO on taxol as second-line therapy for ovarian Ca.
Oncology (Williston Park); 1990 Jul; 4(7):16. PubMed ID: 1975201
[No Abstract] [Full Text] [Related]
14. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
Hu L; Hofmann J; Holash J; Yancopoulos GD; Sood AK; Jaffe RB
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6966-71. PubMed ID: 16203789
[TBL] [Abstract][Full Text] [Related]
15. [Advances in the treatment of ovarian carcinoma].
Pfisterer J; du Bois A; Hilpert F; Wagner U; Meier W
Dtsch Med Wochenschr; 2004 Feb; 129(8):379-84. PubMed ID: 14961446
[No Abstract] [Full Text] [Related]
16. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
[TBL] [Abstract][Full Text] [Related]
17. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples.
Penson RT; Oliva E; Skates SJ; Glyptis T; Fuller AF; Goodman A; Seiden MV
Gynecol Oncol; 2004 Apr; 93(1):98-106. PubMed ID: 15047220
[TBL] [Abstract][Full Text] [Related]
18. Use of chemotherapy for ovarian cancer during human pregnancy: case report and literature review.
Mantovani G; Gramignano G; Mais V; Melis GB; Parodo G; Carrucciu GM
Eur J Obstet Gynecol Reprod Biol; 2007 Apr; 131(2):238-9. PubMed ID: 16698170
[No Abstract] [Full Text] [Related]
19. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy for ovarian cancer: an evidence-based approach.
Geisler JP; Manahan KJ; Wiemann MC
Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
